[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"female-fertility\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:female-fertility":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100638517","late-effects-of-cancer-therapies-on-gonadal-function-fertility-efficiency-of-fertility-preservation-procedures-and-pregnancy-outcomes-100638517",false,"NCT07622537","Late Effects of Cancer Therapies on Gonadal Function, Fertility, Efficiency of Fertility Preservation Procedures and Pregnancy Outcomes","Follow-AYA","Inclusion Criteria:\n\n* Female and male cancer patients aged between 15 and 39 years at diagnosis.\n* First diagnosed with any cancer disease between 01\u002F01\u002F2000 and 31\u002F12\u002F2025\n* Treated with chemotherapy and\u002For targeted therapy\u002Fimmunotherapy and\u002For radiotherapy\u002F radioactive iodine therapy and\u002For testis\u002Fscrotal or gynaecological surgery.\n* Information on treatment received available.\n\nExclusion Criteria:\n\n* Pre-existing known POI at cancer diagnosis\n* Cancer treated by surgery alone (except gynaecological\u002Ftesticular surgery)\n* Data from second malignant neoplasm diagnose and treatment\n* Adult subject of a measure of legal protection and\u002For patients with serious mental disorders","ALL","15 Years","39 Years",{"count":20,"type":21},4000,"ESTIMATED","OBSERVATIONAL","In the past two decades, evidence-based knowledge on the prevalence and risk factors for fertility impairment, including infertility, following cancer and numerous cancer treatment regimens has significantly increased. However, data remains mostly insufficient for individualized prediction of (future) fertility potential, including success of artificial reproductive technologies (ART). Furthermore, therapies have become increasingly complex. Recent treatment regimens have continuously implemented novel treatment approaches (e.g. immune therapies such as checkpoint inhibitors) for which no comprehensive data regarding its impact on fertility and pregnancy outcomes is available, yet.\n\nIt is crucial to carefully balance risk-benefit between fertility preservation (FP) procedures and potential of gonadal function\u002Ffertility impairment, to examine the efficiency and safety, as well as to assess patients' satisfaction regarding the FP procedures. Answering these questions is highly relevant as it has been shown that fertility capacity and post-treatment gonadal function may represent a significant part of the quality of life in young cancer survivors.\n\nThe study therefore aim to set up a large-scale network structure of emerging data collection programmes to evaluate the gonadotoxic risks, including the prevalence and course of ovarian\u002Ftesticular dysfunction and\u002For fertility impairment and premature ovarian insufficiency\u002Foligo\u002Fazoospermia following specific treatments, identification of further risk factors and predictive markers to enhance precision survivorship research in this field. Additionally, data on the use of fertility preservation\u002Ffertility treatment and patients' satisfaction related to these procedures in Europe shall be analysed to support patient-centric care.\n\nReproductive health counselling should not be restricted to evaluating the individual risk of gonadotoxicty and offering fertility preservation to those at risk. It also includes the sexual health, the use of post-cancer treatment contraception for those recommended to delay attempting pregnancy after a cancer diagnosis and the identification of potential obstetrical and neonatal risks to provide individualized, risk-adapted follow-up during pregnancy. An increased risk of obstetrical and neonatal complications has been reported for several conditions, including preterm delivery, pre-eclampsia, cardiac dysfunction, and gestational diabetes. Most available studies are based on population registry and lack of detailed information on critical factors such as the impact of the timing of pregnancy, method of conception or the type of cancer treatment received (e.g pelvic irradiation, anthracycline, targeted therapy, immunotherapy…), all of which may influence the outcomes.\n\nThe main objectives of this retrospective analysis of European ongoing adolescent and young adult (AYA) cancer patient cohorts are:\n\n• To establish harmonized databases with clinical data on pre- and post-cancer therapy and reproductive outcomes in AYA patients followed longitudinally.\n\n• To evaluate the impact of cancer treatment on long-term fertility according to cancer type and individual patients' characteristics (pre- and post-treatment) in male and female AYA populations.\n\n• To evaluate effect of cancer therapies on ovarian function in female AYA patients\n\n• To evaluate long-term effect on the endocrine function of the testis in male AYA patients i.e., the frequency of hypogonadism.\n\n• To evaluate the obstetrical and neonatal outcomes according to the disease and treatment.",[25,26,27,28,29,30],"Cancer","Infertility","Late Effects","Female Fertility","Male Fertility","AYA Cancer Survivors",[32,33,34],"cancer treatment induced late effects","infertility after cancer","AYA cancer survivours","NOT_YET_RECRUITING","2026-05-27",{"date":38,"type":39},"2026-06-03","ACTUAL",{"date":41,"type":21},"2026-06-01",{"date":43,"type":21},"2035-07-31",{"name":45,"class":46},"Karolinska Institutet","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":73,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100629184","pesticides-and-infertility-oxidative-stress-via-circulating-cell-free-dna-and-gutgenital-microbiome-signatures-in-women-with-endometriosis-100629184","NCT07471373","Pesticides and Infertility: Oxidative Stress Via Circulating Cell-free DNA and Gut\u002FGenital Microbiome Signatures in Women With Endometriosis","PestiEndoMicro","Inclusion Criteria:\n\n* The \"case\" group will include:\n* All women aged 18 to 43, with confirmed endometriosis and endometriosis grade 3 or 4 as defined by the 1985 revised version of the American Society of Reproductive Medicine.\n* The \"control\" group will include:\n* All women aged between 18 and 43, whose infertility problem is proven male infertility and who do not have endometriosis identified by biological, genetic and clinical tests.\n* The following criteria will apply to both groups:\n* All women who have not received antibiotic treatment in the three months preceding inclusion and who are not participating in any pharmacological study.\n* All women who are covered under the national social security health insurance scheme.\n* All women who have signed a written informed consent form, thereby confirming their participation in the study after a period of free and informed reflection.\n\nExclusion Criteria:\n\n* All women aged 44 and over.\n* Women who are overweight, obese or anorexic.\n* Women taking antibiotics 3 months prior to inclusion, or participating in a drug study.\n* All women under anti-GnRH treatment, pregnant or suffering from a chronic inflammatory disease such as Crohn's disease, polycystic ovary syndrome, etc.\n* All women whose endometriosis has not been formally confirmed by the tests offered by the Reproductive Medicine and Biology Department, CECOS de Picardie, CHU Amiens-Picardie.\n* All patients under guardianship, curators or safeguard of justice.\n* All patients who have not signed the written consent confirming their participation in the study, after a period of free and informed reflection.\n* Any patient who withdraws her consent for participation in the study.",true,"FEMALE","18 Years","43 Years",{"count":59,"type":21},160,"INTERVENTIONAL",[62],"NA","This project PestiEndoMicro aims to provide an innovative approach, studying endometriosis under the genital and gut microbiota scope. To realize this project, the investigators are planning to dose cfDNA to assess the oxidative stress caused by endometriosis and study its epigenetics. At the same time, the investigators will take a pragmatic approach by assessing pesticide exposure in these patients and estimate the correlation between gut or genital dysbiosis and chemical agent exposure. Also, the investigators will take the initiative to use classic culture, qPCR techniques, and NGS to establish signatures in vaginal, endometrial and gut microbiota in patients with endometriosis. With these approaches, the goal is to gain more knowledge about endometriosis and optimize early diagnosis by establishing a signature in the genital and gut microbiota, but also by dosing the cfDNA. By doing so the investigators could open new opportunities to develop new therapeutic strategies for endometriosis.",[65,26,28,66,67,68,69,70,71,72],"Endometriosis","Cell Free DNA","Genital Microbiota","Vaginal Microbiota","Endometrial Microbiota","Pesticides","Gut Microbiota","Epigenetics",[65,26,74,75,76,77,78,79,80,81],"Female fertility","cell free DNA","genital microbiota","vaginal microbiota","endometrial microbiota","pesticides","gut microbiota","epigenetics","RECRUITING","2026-05-12",{"date":85,"type":39},"2026-05-15",{"date":87,"type":39},"2026-02-27",{"date":89,"type":21},"2028-05",{"name":91,"class":46},"Centre Hospitalier Universitaire, Amiens",1,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":55,"minAge":100,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":60,"phases":104,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":117},"100579624","a-study-to-assess-the-effect-of-libifem-vl-gf-01-on-fertility-in-women-with-diminished-ovarian-reserve-100579624","NCT06826716","A Study to Assess the Effect of Libifem® (VL-GF-01) on Fertility in Women With Diminished Ovarian Reserve","A Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Effect of Libifem® (VL-GF-01) on Fertility in Women With Diminished Ovarian Reserve","Inclusion Criteria:\n\n1. Individuals ready to give voluntary, written informed consent to participate in the study.\n2. Women of age between 25 to 35 years who wish to conceive.\n3. Women with BMI between 18.5 to 34.9 kg\u002Fm2 (both values included).\n4. Women who are unable to conceive for at least one year with an unprotected sexual life.\n5. Women engaging in sexual act regularly and agree to continue the same at least twice a week during the study.\n6. Women with bilateral tubal patency as confirmed by reports (within last one year from screening) of Hysterosalpingography (HSG) or Sonosalpingography (SSG).\n7. Eumenorrheic women with a regular menstrual cycle of 28 ± 5 days.\n8. Women with Hemoglobin levels greater than or equal to 10 g\u002FdL.\n9. Women with Anti-Mullerian hormone (AMH) greater than 0 and less than 1.5 ng\u002Fml on day 2 of menstrual cycle.\n10. Females with serum Thyroid-stimulating hormone (TSH) levels between 0.4 mIU\u002FL to 5 mIU\u002FL \\[both values inclusive\\] with or without medication.\n11. Women who are not pregnant during the time of screening as assessed by UPT.\n12. Women who have never undergone IVF procedure.\n13. Women with their male partners having an acceptable serum analysis report as per PI.\n14. Women willing to complete all study-related assessments and to complete all clinical study visits as per the protocol.\n\nExclusion Criteria:\n\n1. Any chronic illness like hyper-prolactinemia.\n2. Females diagnosed with stage 3 and stage 4 Endometriosis.\n3. Females with a history of recurrent pregnancy loss (defined as ≥ 2 failed clinical pregnancies before 22 weeks of gestational age).\n4. Females clinically diagnosed with Polycystic Ovarian Syndrome (PCOS).\n5. Females with a prior history (within the last 6 months from screening) of ≥3 cycles of ovulation induction.\n6. History of ovarian hyper-response.\n7. History of any endocrine abnormality (eg: Adrenal gland disorders, pituitary disorders, endocrine diseases, dyslipidemia, etc.).\n8. Females previously diagnosed with hyperparathyroidism and\u002For hyperthyroidism.\n9. Females with a history of any psychiatric disorder.\n10. Currently undergoing or have previously undergone Hormone Therapy (HT) for treatment of fertility in the previous 6 months.\n11. Currently consuming Ayurvedic\u002Fdietary supplements, and\u002For currently consuming steroids or if consumed in the last 3 months before screening.\n12. Currently consuming cytotoxics and immunosuppressants.\n13. History of uncontrolled hypertension and\u002For systolic blood pressure greater than equal to 140 mmHg and\u002For diastolic blood pressure greater than equal to 90 mmHg.\n14. Fasting blood glucose (FBG) greater than or equal to 126 mg\u002FdL.\n15. Participation in other clinical studies in the past 3 months.\n16. History of alcohol or drug abuse in the 12 months prior to screening.\n17. History of cancer.\n18. Hematological disorders.\n19. History or presence of any Sexually Transmitted Disease (STD).\n20. History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the potential individual at risk because of participation in the study, or influences the results or the potential individual's ability to participate in the study.\n21. History or presence of HIV, cardiovascular, gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs (i.e. Crohn's disease, short bowel, acute or chronic pancreatitis or pancreatic insufficiency).\n22. Lactating women","25 Years","35 Years",{"count":103,"type":21},150,[62],"The present study is a randomized, double-blind, placebo-controlled, parallel clinical study. Approximately 156 participants will be screened, and considering a screening failure rate of 20%, not more than 124 participants will be randomized in a ratio of 1:1 to receive either Libifem® or placebo and will be assigned a unique randomization code. Each group will have not less than 50 completed participants after accounting for a dropout\u002Fwithdrawal rate of 20%.",[28],"2025-02-11",{"date":109,"type":39},"2025-02-14",{"date":111,"type":21},"2025-02-10",{"date":113,"type":21},"2025-12-10",{"name":115,"class":116},"Vedic Lifesciences Pvt. Ltd.","INDUSTRY",7]